Healthcare of Ontario Pension Plan Trust Fund Takes Position in GSK plc (NYSE:GSK)

Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in GSK plc (NYSE:GSKGet Rating) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 34,100 shares of the pharmaceutical company’s stock, valued at approximately $1,484,000.

Several other institutional investors and hedge funds also recently made changes to their positions in GSK. Assetmark Inc. grew its position in shares of GSK by 42.8% during the 2nd quarter. Assetmark Inc. now owns 9,650 shares of the pharmaceutical company’s stock worth $420,000 after purchasing an additional 2,892 shares in the last quarter. Morningstar Investment Services LLC boosted its position in shares of GSK by 6.3% during the 1st quarter. Morningstar Investment Services LLC now owns 7,110 shares of the pharmaceutical company’s stock worth $310,000 after acquiring an additional 421 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its position in shares of GSK by 13.6% during the 1st quarter. Mercer Global Advisors Inc. ADV now owns 123,778 shares of the pharmaceutical company’s stock worth $5,392,000 after acquiring an additional 14,860 shares in the last quarter. Mutual Advisors LLC boosted its position in shares of GSK by 17.9% during the 1st quarter. Mutual Advisors LLC now owns 24,354 shares of the pharmaceutical company’s stock worth $1,061,000 after acquiring an additional 3,701 shares in the last quarter. Finally, Cerity Partners LLC boosted its position in shares of GSK by 20.9% during the 2nd quarter. Cerity Partners LLC now owns 71,111 shares of the pharmaceutical company’s stock worth $3,097,000 after acquiring an additional 12,275 shares in the last quarter. Institutional investors and hedge funds own 16.86% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reduced their price target on shares of GSK from GBX 1,750 ($20.69) to GBX 1,500 ($17.74) in a research report on Wednesday, September 7th. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 11th. Morgan Stanley increased their price objective on shares of GSK from GBX 1,550 ($18.33) to GBX 1,650 ($19.51) in a research note on Wednesday, October 12th. TheStreet downgraded shares of GSK from a “b” rating to a “c+” rating in a research note on Monday, August 29th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of GSK from GBX 1,900 ($22.47) to GBX 1,600 ($18.92) in a research note on Tuesday, November 8th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $1,608.33.

GSK Price Performance

GSK stock opened at $33.69 on Friday. The company has a fifty day moving average price of $31.45 and a 200-day moving average price of $37.07. The company has a market capitalization of $68.51 billion, a P/E ratio of 4.13, a PEG ratio of 1.20 and a beta of 0.67. GSK plc has a 52-week low of $28.47 and a 52-week high of $46.97. The company has a debt-to-equity ratio of 2.22, a quick ratio of 0.74 and a current ratio of 0.97.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 12th. Stockholders of record on Friday, November 18th will be paid a dividend of $0.3695 per share. This represents a $1.48 annualized dividend and a dividend yield of 4.39%. The ex-dividend date of this dividend is Thursday, November 17th. GSK’s payout ratio is currently 15.20%.

About GSK

(Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

See Also

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKGet Rating).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.